BioCardia (BCDA) Q4 2024 earnings summary

Executive summary

• Announced primary outcome data from the CardiAMP Heart Failure Trial, showing strong signals of benefit in key clinical endpoints for patients with ischemic heart failure treated with CardiAMP cell therapy, despite not meeting the primary endpoint due to the six-minute walk test component.

• Reported 2024 financial results and business highlights, including progress in clinical trials for CardiAMP and CardiALLO cell therapies.

• Completed key milestones in CardiAMP HF Trial, with data analysis near completion and results to be presented at ACC 2025.

• Regulatory discussions are ongoing with both the FDA and Japan's PMDA, with the potential for conditional or full approval in Japan based on the robust data set.

• Launched commercial Morph DNA steerable introducer devices for clinical and commercial use.

Financial highlights

• Total expenses decreased 35% year-over-year to $8.1 million in 2024, primarily due to lower R&D costs after completion of the CardiAMP Heart Failure trial.

• Net loss decreased to $7.9 million in 2024 from $11.6 million in 2023, reflecting lower R&D and SG&A expenses.

• R&D expenses fell 43% to $4.4 million, while SG&A expenses dropped 16% to $3.7 million.

• Revenues were $58,000 in 2024, down from $477,000 in 2023, mainly due to completion of performance obligations.

• Cash and cash equivalents at year-end totaled $2.4 million, up from $1.1 million at the end of 2023.

Outlook and guidance

• R&D expenses are expected to increase modestly in 2025 as clinical programs advance in the US and Japan.

• Anticipates presenting CardiAMP HF data at ACC 2025, with potential to support product registration.

• Plans to submit clinical data to FDA and Japan's PMDA and accelerate enrollment in CardiAMP HF II Trial.

• SG&A expenses are projected to remain near 2024 levels, with a moderate increase in cash burn anticipated.

• Upcoming milestones include Data Safety Monitoring Board review for CardiALLO and publication of BCDA-02 cohort data.